Premium
Cutaneous leishmaniasis: successful treatment with itraconazole
Author(s) -
Consigli Javier,
Danielo Cristian,
Gallerano Verónica,
Papa Mariana,
Guidi Andrés
Publication year - 2006
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2004.02429.x
Subject(s) - itraconazole , medicine , leishmaniasis , amphotericin b , protozoa , dermatology , cutaneous leishmaniasis , mucocutaneous zone , pharmacotherapy , leishmania , disease , amastigote , immunology , antifungal , parasite hosting , microbiology and biotechnology , biology , world wide web , computer science
Background Leishmaniasis is a disease produced by several species of protozoa of the Leishmania genus. These protozoa are injected into the human bloodstream by sandflies. The symptomathology, either cutaneous, mucocutaneous or visceral, depends on the infective species and the immune status of the patient. Antimonial drugs are the mainstay treatment for all the clinical forms of the disease. Amphotericin B is the second‐choice drug. Methods We report two clinical cases of cutaneous leishmaniasis treated with itraconazole. One case was a relapsing form unresponsive to conventional therapy. Results Both patients achieved fast resolution of their lesions with no secondary effects. Conclusions Itraconazole may be a valid option for the treatment of cutaneous leishmaniasis, mainly in those cases unresponsive to conventional drugs.